ArticleExperimental & molecular medicine2025
The dual roles of peptidoglycans: NOD1 and NOD2 inversely regulate bone metabolism.
Article in Experimental & molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting the Gut-Bone Axis with Prebiotics, Probiotics, Synbiotics, and Postbiotics: From Mechanistic Plausibility to Clinical Bone Outcomes.Nutrients · 2026Review
- Multiscale bone remodeling in COVID-19: from osteoimmune signaling to structural and mechanical impairment.Frontiers in bioengineering and biotechnology · 2026Review
- IgG/IgM-coated gut microbiota in schizophrenia: associations with inflammation disease activity.Frontiers in psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Gut microbiota and microbial components are known to regulate bone metabolism. Peptidoglycan, a key bacterial cell wall component, is recognized by NOD1 and NOD2. Muramyl dipeptide (MDP), a ligand for NOD2 found in most bacteria, increases bone mass by promoting bone formation via Runx2 and β-catenin. However, the effects of NOD1 ligands, such as L-Ala-γ-D-glu-meso-diaminopimelic acid (TriDAP) from Gram-negative bacteria, remain poorly understood. Here, we demonstrate that, unlike MDP, TriDAP elicits bone resorption by decreasing osteoblast and Runx2 levels and increasing osteoclasts in the distal femurs of mice intraperitoneally administered TriDAP. This treatment inhibited osteoblast differentiation by downregulating Runx2 expression and also decreased the protein stability of Runx2 by increasing its ubiquitination. TriDAP, but not MDP, reduced the expression of IκB and increased NF-κB transcriptional activity in osteoblasts. The inhibition of osteoblast differentiation by TriDAP occurred through NF-κB activation and NOD1 recognition. TriDAP exhibited a marginal increase in osteoclast differentiation in the presence of RANKL, but it enhanced osteoclast differentiation in an osteoblast-osteoclast co-culture system. This suggests that TriDAP directly affects osteoblasts and indirectly affects osteoclasts. TriDAP did not induce osteoclast differentiation in the presence of NOD1-deficient osteoblasts. Other NOD1 ligands, C12-iE-DAP and C14-Tri-LAN-Gly, also inhibited osteoblastogenesis and promoted osteoclastogenesis, similar to TriDAP. Bacillus cereus peptidoglycan preferentially stimulates NOD1 but not NOD2, leading to increased bone resorption. In conclusion, activation of NOD1 in osteoblasts plays a role in regulating bone homeostasis by enhancing bone resorption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.